AP-101 is a recombinant human antibody designed to selectively deplete toxic, misfolded forms of SOD1 while preserving the protective function of physiological SOD1. By targeting only the pathological conformations, AP-101 aims to disrupt a key driver of ALS progression without lowering total SOD1 levels.